News and Announcements
The Hydroponics Company Completes Placement at $8 million & Increases Share Price by 136.1%
- Published January 11, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- The Hydroponics Company (ASX: THC or Company) advises that it has completed an $8m share placement to expand both its’ Canadian and Australian businesses.
- THC confirms that the placement was fully subscribed with funds raised from both sophisticated and institutional investors. Notably, 7 new institutional investors to join the register.
- The Placement was conducted at an issue price of $0.63 a share, representing a 19.8% discount to THC’s 5 day VWAP (5 – 11 December 2017).
- The Hydroponics Company has experienced share price growth of 136.1%.
To read the full article on the ASX please click here.
About Canndeo Ltd
Canndeo is an Australian based, internationally linked and vertically integrated medicinal cannabis company.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
